Jonathan Simon Cebon
La Trobe University · 547 works · 44,731 citations · h-index 89
Top works
- Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma
- Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations
- Randomized Phase III Study of Temozolomide Versus Dacarbazine in the Treatment of Patients With Advanced Metastatic Malignant Melanoma
- The repertoire of mutational signatures in human cancer
- Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology.
- Pan-cancer analysis of whole genomes
- Type I IFNs Enhance the Terminal Differentiation of Dendritic Cells
- Whole-genome landscapes of major melanoma subtypes
- Tumor Antigen Expression in Melanoma Varies According to Antigen and Stage
- Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy
- The evolutionary history of 2,658 cancers
- Overall Survival and Durable Responses in Patients With BRAF V600–Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib
- CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity
- Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
- Pooled Analysis Safety Profile of Nivolumab and Ipilimumab Combination Therapy in Patients With Advanced Melanoma
- Effects of Bacterially Synthesized Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor in Patients with Advanced Malignancy
- Functionally distinct dendritic cell (DC) populations induced by physiologic stimuli: prostaglandin E2 regulates the migratory capacity of specific DC subsets
- Patterns of somatic structural variation in human cancer genomes
- Combined BRAF (Dabrafenib) and MEK Inhibition (Trametinib) in Patients With BRAF V600 -Mutant Melanoma Experiencing Progression With Single-Agent BRAF Inhibitor
- Filgrastim in Patients with Chemotherapy-Induced Febrile Neutropenia: A Double-Blind, Placebo-Controlled Trial